Stay updated on Gilteritinib Combo for Newly Diagnosed AML Clinical Trial

Sign up to get notified when there's something new on the Gilteritinib Combo for Newly Diagnosed AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Gilteritinib Combo for Newly Diagnosed AML Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value 08 has recently changed to 23 on the webpage, indicating a significant update in the context of medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-05-24T07:56:07.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 6 to 7, indicating a recent update in the context of Medical and healthcare-related publications and documentation.
    Difference
    0.3%
    Check dated 2024-05-22T07:46:02.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 03 27 has been updated to 05 08 on the webpage, indicating a recent change in the information related to the study of Gilteritinib, Venetoclax, and Azacitidine as a combined treatment for people newly diagnosed with Acute Myeloid Leukemia, possibly reflecting new developments or updates in the medical and healthcare-related publications and documentation.
    Difference
    0.6%
    Check dated 2024-05-09T02:09:46.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:50:44.000Z thumbnail image

Stay in the know with updates to Gilteritinib Combo for Newly Diagnosed AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Gilteritinib Combo for Newly Diagnosed AML Clinical Trial page.